Immunocore Holdings plc (NASDAQ:IMCR – Free Report) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will earn $7.53 per share for the year. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.
Several other analysts also recently weighed in on the stock. Guggenheim lowered Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. Needham & Company LLC reissued a “buy” rating and set a $71.00 price target on shares of Immunocore in a research report on Friday, January 10th. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $72.00 to $38.00 in a report on Monday, November 11th. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, UBS Group started coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $65.64.
Immunocore Trading Down 0.6 %
IMCR stock opened at $32.08 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company has a market capitalization of $1.60 billion, a PE ratio of -33.77 and a beta of 0.76. The firm’s 50-day moving average is $30.54 and its 200 day moving average is $33.23. Immunocore has a 12 month low of $27.69 and a 12 month high of $76.98.
Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.59) EPS.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its holdings in Immunocore by 10.5% in the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after acquiring an additional 668,382 shares in the last quarter. Primecap Management Co. CA raised its position in shares of Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after purchasing an additional 520,950 shares during the last quarter. Millennium Management LLC boosted its stake in Immunocore by 124.4% in the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after purchasing an additional 333,167 shares in the last quarter. Two Sigma Advisers LP increased its stake in Immunocore by 65.6% during the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock valued at $23,587,000 after purchasing an additional 300,200 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after buying an additional 109,206 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Recommended Stories
- Five stocks we like better than Immunocore
- Insider Trading – What You Need to Know
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- About the Markup Calculator
- What Does the Future Hold for Eli Lilly?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.